10 news items
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRNX
10 Jun 24
of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor
Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
CRNX
3 Jun 24
clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly. Data presented included results of the Phase 3
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)
CRNX
3 Jun 24
London Hospitals NHS Foundation Trust and TouCAHn investigator. "Atumelnant's unique ability to inhibit ACTH directly at its receptor sets it apart
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
. (NASDAQ:CRNX) today presented findings from its clinical development program evaluating oral, once-daily investigational paltusotine
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
CRNX
30 May 24
. "As we forge ahead on the development and potential commercialization of our investigational product candidates, paltusotine and atumelnant, as well
8b8w8o1oxhqij86018lu1qdprsh3glp
CRNX
22 May 24
, an investigational
c6kblg9wb61oa4v5a359027so3ci93ksb0ya rmsholf
CRNX
10 May 24
of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor
9ul3dm6ly2hpcfyei1tuxbqvzwcgsvksmlas6iw3tdv1w789dzph9
CRNX
8 May 24
studies of atumelnant* (CRN04894), our investigational, once-daily oral ACTH receptor antagonist, in development for the treatment of people
dvf0eqity
CRNX
11 Apr 24
, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral
nq43clqm3gwbel0 k4g4
CRNX
19 Mar 24
, once-daily investigational paltusotine for the treatment of acromegaly. PATHFNDR-2
- Prev
- 1
- Next